percentage of americans on glp 1 GLP-1 Survey: 75% Users Report Reduced Spending Food, Alcohol The GLP-1 Access Gap: Mapping

Clinical trials of tirzepatide showed 16 to 22.5 percent body weight loss over 72 weeks at doses of 10mg to 15mg weekly

Decreased expression Rheumatoid arthritis Results from three experimental studies suggest that GLP-1RAs (lixisenatide, exenatide, and dulaglutide) show therapeutic potential for treating RA through similar mechanisms

19 Special Regulatory Procedures Fast track designation The FDA is required to facilitate the development and expedite the review of drugs and biologics that are intended for the treatment of a serious or life-threatening disease or condition and that demonstrate the potential to address unmet medical needs

Weight loss peptides : Rapid weight loss can disrupt cycles temporarily (normal response to calorie deficit)

2022;57(Suppl 1):58